ArticleCancers2019
Adjuvant Ipilimumab in High-Risk Uveal Melanoma.
Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Immune checkpoint inhibitor-associated pituitary-adrenal dysfunction: A systematic review and meta-analysis.Cancer medicine · 2019Pooled it
- The Future of Checkpoint Inhibitors in Uveal Melanoma: A Narrative Review.Ophthalmology and therapy · 2024Review
- Ten years' blindness of the right eye: A rare presentation of an orbital melanoma.SAGE open medical case reports · 2023Article
- 25 Years of Adjuvant Therapy in Melanoma: A Perspective on Current Approvals and Insights into Future Directions.Current oncology reports · 2022Review
- Prognostic and Functional Analysis ofDisease markers · 2022Article
- Review
- Review
- Molecular Insights and Emerging Strategies for Treatment of Metastatic Uveal Melanoma.Cancers · 2020Review
- Novel Approaches to the Systemic Management of Uveal Melanoma.Current oncology reports · 2020Review
- Targeting Epigenetic Modifications in Uveal Melanoma.International journal of molecular sciences · 2020Review
- The Role of Immune Checkpoint Blockade in Uveal Melanoma.International journal of molecular sciences · 2020Review
- Uveal Melanoma.Cancers · 2019Article
- Melanoma and Vitiligo: In Good Company.International journal of molecular sciences · 2019Review
- Current Perspectives in Cancer Immunotherapy.Cancers · 2019Review
- Review
- Immunobiology of Uveal Melanoma: State of the Art and Therapeutic Targets.Frontiers in oncology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Uveal melanoma is a common intraocular malignant tumor that is uniformly fatal once metastatic. No effective adjuvant therapy currently exists to reduce the risk of distant metastasis after definitive treatment of the primary lesion. Immunotherapy has been used effectively in the adjuvant setting in locally advanced cutaneous melanoma. We performed a Phase I/II clinical trial of adjuvant ipilimumab in high-risk primary uveal melanoma with distant metastasis-free survival (DMFS) as the primary objective. A total of 10 patients with genomically high-risk disease were treated: three at a dose of 3 mg/kg and seven at 10 mg/kg. Two of the seven patients at the higher dose had to discontinue therapy secondary to grade 3 toxicity. At 36 months follow-up, 80% of patients had no evidence of distant disease (95% CI, 58.7⁻100). With recent advancements in CTLA-4 inhibition, PD-1 inhibition, and combined checkpoint blockade, immunotherapy is a promising avenue of treatment in uveal melanoma. Further clinical trials are needed to elucidate the role of immunotherapy in the adjuvant setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.